Skip to content

Aurion Biotech Wins Clinical Advance of the Year Award at Biotech Week Boston

Recognition for its innovative cell therapy for corneal endothelial diseases

September 19, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has received the Clinical Advance of the Year award from Biotech Week Boston.

“Aurion Biotech is advancing a game-changing cell therapy for a serious, sight-threatening condition: corneal endothelial disease. We thank the sponsors of Biotech Week Boston for their recognition of our accomplishments,” said Greg Kunst, Aurion’s chief executive officer. “Garnering this kind of attention is another step in helping us achieve our mission to serve millions of patients around the world.”

Biotech Week Boston is a weeklong gathering of industry executives, organized into 10 specialized conferences covering all aspects of biotech, from manufacturing, to innovation, to diversity and inclusion, to compliance and finance and accounting.

Aurion Biotech’s cell therapy recently received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), for the treatment of bullous keratopathy, marking the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease. The company will initiate clinical trials in the U.S. in the second half of 2023.

About Aurion Biotech

With offices in Seattle, Cambridge and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company will initiate clinical trials in the U.S. in 2023. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com.

Media Contacts